Your browser is no longer supported. Please, upgrade your browser.
SRPT Sarepta Therapeutics, Inc. daily Stock Chart
Sarepta Therapeutics, Inc.
Index- P/E- EPS (ttm)-3.37 Insider Own5.60% Shs Outstand65.33M Perf Week-3.38%
Market Cap9.64B Forward P/E- EPS next Y-1.94 Insider Trans-3.76% Shs Float62.51M Perf Month9.78%
Income-216.40M PEG- EPS next Q-0.82 Inst Own90.80% Short Float14.45% Perf Quarter5.17%
Sales241.40M P/S39.94 EPS this Y84.30% Inst Trans5.68% Short Ratio7.69 Perf Half Y89.70%
Book/sh10.68 P/B13.82 EPS next Y49.60% ROA-18.60% Target Price189.17 Perf Year213.35%
Cash/sh14.53 P/C10.16 EPS next 5Y-0.20% ROE-29.20% 52W Range42.97 - 176.50 Perf YTD165.26%
Dividend- P/FCF- EPS past 5Y30.00% ROI-14.20% 52W High-16.38% Beta1.14
Dividend %- Quick Ratio9.90 Sales past 5Y32.90% Gross Margin92.20% 52W Low243.47% ATR5.57
Employees255 Current Ratio10.90 Sales Q/Q110.00% Oper. Margin-84.20% RSI (14)57.03 Volatility2.92% 3.94%
OptionableYes Debt/Eq0.63 EPS Q/Q-45.50% Profit Margin-89.60% Rel Volume1.42 Prev Close152.83
ShortableYes LT Debt/Eq0.62 EarningsAug 08 AMC Payout- Avg Volume1.17M Price147.59
Recom1.70 SMA202.81% SMA509.84% SMA20057.34% Volume1,661,781 Change-3.43%
Sep-14-18Resumed BofA/Merrill Buy $199
Sep-06-18Initiated Credit Suisse Outperform $178
Aug-01-18Upgrade Morgan Stanley Equal-Weight → Overweight
Jun-21-18Reiterated Robert W. Baird Outperform $120 → $202
Jun-20-18Reiterated Needham Buy $109 → $204
Jun-19-18Reiterated H.C. Wainwright Buy $96 → $267
May-18-18Reiterated Goldman Buy $84 → $127
May-11-18Upgrade Barclays Equal Weight → Overweight $55 → $107
May-07-18Reiterated Needham Buy $75 → $109
May-07-18Reiterated H.C. Wainwright Buy $90 → $96
Mar-21-18Downgrade Morgan Stanley Overweight → Equal-Weight
Mar-13-18Reiterated H.C. Wainwright Buy $75 → $92
Jan-22-18Initiated RBC Capital Mkts Outperform
Jan-04-18Initiated Janney Buy $75
Dec-01-17Initiated H.C. Wainwright Buy $75
Oct-06-17Resumed Goldman Buy $71
Oct-02-17Upgrade Morgan Stanley Equal-Weight → Overweight
Jul-20-17Reiterated RBC Capital Mkts Outperform $60 → $64
Apr-28-17Reiterated RBC Capital Mkts Outperform $91 → $60
Apr-05-17Upgrade SunTrust Hold → Buy
Sep-21-18 12:01PM  Sarepta investors, analysts shrug off E.U. setback for Duchenne drug American City Business Journals
06:48AM  Sarepta expected, but is disappointed by European regulators decision on DMD treatment MarketWatch
06:30AM  Sarepta Receives Negative CHMP Re-examination Opinion for Eteplirsen GlobeNewswire
Sep-12-18 01:10PM  Corrective Action in This Market Is Often Quite Hidden +5.07%
Sep-11-18 07:43PM  Why Sarepta Therapeutics, Inc. Stock Jumped 18.8% Higher in August Motley Fool
Sep-10-18 02:17PM  Six Biotechnology Names on My Watch List
Sep-07-18 05:05PM  Sarepta Therapeutics CEO has a 'big ambition' for muscular dystrophy gene therapy CNBC
03:34PM  Sarepta Therapeutics CEO on soaring stock and drug develo... CNBC Videos
09:30AM  Why Is Sarepta Therapeutics (SRPT) Up 6.4% Since Last Earnings Report? Zacks
09:15AM  Today's Bell Ringer, September 7, 2018 CNBC Videos
08:30AM  Sarepta Therapeutics to Recognize World Duchenne Awareness Day at NASDAQ Opening Bell Ceremony GlobeNewswire
Sep-06-18 02:47PM  Credit Suisse Joins Consensus To Prescribe Sarepta Benzinga
Sep-04-18 01:51PM  The Market Is Finally Pulling Back
08:30AM  Sarepta Therapeutics to Present at Two Upcoming Investor Conferences GlobeNewswire
Aug-31-18 06:36PM  Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Aug-30-18 02:00PM  CRISPR without consequences? Startup's drug shows promise in animal study American City Business Journals
01:38PM  A Lesson to Learn From Thursday's Market Action
12:47PM  Scholar Rock stock tumbles 11% as Pfizer discontinues similar medication MarketWatch
08:28AM  Pfizer stops developing therapy for the rare disease Duchenne muscular dystrophy MarketWatch
08:00AM  Today's Research Reports on Trending Tickers: Regeneron Pharmaceuticals and Sarepta Therapeutics ACCESSWIRE
Aug-29-18 05:12PM  Time to Take Some Profits in Sarepta Therapeutics Stock InvestorPlace
Aug-23-18 08:00AM  Today's Research Reports on Trending Tickers: Conatus Pharmaceuticals and Sarepta Therapeutics ACCESSWIRE
Aug-22-18 12:11AM  Edited Transcript of SRPT earnings conference call or presentation 8-Aug-18 8:30pm GMT Thomson Reuters StreetEvents
Aug-20-18 11:50AM  Weekly CEO Buys Highlight
08:30AM  Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program GlobeNewswire
Aug-17-18 07:45AM  Jim Cramer Weighs In On NuStar Energy, Royal Dutch Shell, United Rentals And More Benzinga
Aug-16-18 07:00AM  Market Morning: Gene Therapy Deregulation, Amazon to the Movies, SEC On Musks Tail Market Exclusive
Aug-15-18 02:01PM  Prepare For the Worst but Stay Positive
Aug-14-18 02:05PM  Little Fear of Missing Out as Stocks Hold Gains
Aug-13-18 12:36PM  Overly Aggressive Dip Buyers Finally Trapped
Aug-10-18 03:17PM  GlycoMimetics Stock Has Substantial Upside InvestorPlace
07:52AM  Is Sarepta Therapeutics Stock a Bargain? Motley Fool
Aug-09-18 05:20PM  Why Sarepta Therapeutics, Inc. Stock Surged Today Motley Fool +9.87%
09:35AM  Sarepta (SRPT) Q2 Loss Narrows, Exondys 51 Drives Sales Zacks
08:40AM  Implied Volatility Surging for Sarepta Therapeutics (SRPT) Stock Options Zacks
Aug-08-18 05:50PM  Sarepta Therapeutics (SRPT) Reports Q2 Loss, Tops Revenue Estimates Zacks
04:47PM  Sarepta Therapeutics: 2Q Earnings Snapshot Associated Press
04:02PM  Sarepta Therapeutics Announces Second Quarter 2018 Financial Results and Recent Corporate Developments GlobeNewswire
04:01PM  Sarepta Therapeutics Signs Long-term Strategic Investment and License Agreements with Lacerta Therapeutics, Gaining Rights to Multiple CNS-targeted Gene Therapy programs and Access to Important Gene Therapy Talent and Tools GlobeNewswire
02:30PM  Sarepta Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
Aug-01-18 10:03AM  Morgan Stanley Buys Into Sarepta Amid Sell-Off, Sees $600M Recurring Opportunity In DMD Candidate Benzinga
Jul-31-18 06:00PM  Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
07:00AM  Free Technical Reports on Sarepta Therapeutics and Three Additional Biotech Equities ACCESSWIRE
Jul-26-18 10:30AM  Sarepta's Clinical Hold Could Be A Solid Biosciences Catalyst, Says Bullish Chardan Analyst Benzinga
09:00AM  Should First Trust Mid Cap Growth AlphaDEX Fund (FNY) Be on Your Investing Radar? Zacks
08:20AM  Today's Research Reports on Trending Tickers: Sarepta Therapeutics and Global Blood Therapeutics ACCESSWIRE
Jul-25-18 04:44PM  Sarepta stock drops after Muscular Dystrophy study halted by FDA MarketWatch
04:34PM  Sarepta Therapeutics Announces that Phase 1/2a Duchenne Muscular Dystrophy (DMD) Micro-Dystrophin Gene Therapy Trial Placed on Clinical Hold Due to an Out-of-Specification Production Lot; No Observed Safety Events GlobeNewswire
Jul-23-18 02:24PM  Sarepta Therapeutics, Inc. and CureDuchenne to Host Webinar on Duchenne Muscular Dystrophy Programs Utilizing Sareptas RNA-Targeted Technology Platforms Business Wire
Jul-20-18 08:30AM  Sarepta Therapeutics to Announce Second Quarter 2018 Financial Results and Recent Corporate Developments on August 8, 2018 GlobeNewswire
Jul-16-18 02:53PM  The 5 Best Growth Stocks of 2018 (So Far) Motley Fool
Jul-13-18 03:35PM  3 Gene Therapy Companies In Hot Pursuit Of A 'One-And-Done' Cure Investor's Business Daily
Jul-08-18 08:30PM  [$$] Patients Win With More Access to Treatments The Wall Street Journal
Jul-06-18 11:47AM  Biogen: Let the Situation Cool Off a Bit Before Buying
Jul-05-18 10:32AM  Sarepta's DMD Portfolio Solid, Sole Drug Dependence Concerns Zacks
Jul-04-18 08:00PM  [$$] A Risky Drug Approval Lesson The Wall Street Journal
06:00AM  Don't Waste Your Money on Cryptocurrencies, These 3 Stocks Are Better Buys Motley Fool
Jul-03-18 11:05AM  Unexciting Holiday Trading
09:30AM  3 Best Gene Therapy Stocks of 2018 (So Far) Motley Fool
Jun-29-18 06:00PM  Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
07:25AM  Free Pre-Market Technical Recap on Sarepta Therapeutics and Three Additional Biotech Stocks ACCESSWIRE
Jun-25-18 02:21PM  Sarepta Therapeutics Could Be Onto Something Big Motley Fool
08:53AM  Analyst: Solid Biosciences A Solid Buy On Sarepta's Progress Benzinga
08:49AM  Are These 3 Red-Hot Gene Therapy Stocks Still Buys? Motley Fool
Jun-23-18 07:15AM  3 Biotech Stocks That Soared This Week: Are They Buys? Motley Fool
Jun-22-18 09:20AM  Big Biotech Stock Pops and Drops This Week Motley Fool -6.23%
08:41AM  DMD Research Veers Toward Gene Therapy: 3 Stocks in Focus Zacks
Jun-21-18 11:12AM  FAANG Stocks Are Being Nailed
08:26AM  Is Sarepta Therapeutics Stock Headed to Over $200 a Share? Motley Fool
08:00AM  Trending: Technology Sector Surges to Record Highs Despite Trade Jitters ETF Database
Jun-20-18 03:23PM  Sarepta Shares Keep Climbing and PTC Therapeutics Bounces Back +6.78%
01:47PM  This Biotech Is Cratering On Sarepta's Success But Could Be 'Superior' Investor's Business Daily
10:55AM  Sarepta Pharma Pushes Two Biotech ETFs to New Highs Zacks
10:00AM  Company News For Jun 20, 2018 Zacks
08:48AM  Sarepta shares rocket 40% on promising early results for DMD gene therapy MarketWatch
08:36AM  Benzinga's Daily Biotech Pulse: Sarepta's DMD Gene Therapy, Anika's Flunked Trial, Eidos To Commence Trading Benzinga
08:32AM  Biotech Stock Roundup: SRPT & SLDB Soar on Positive Data, ANIK & ZIOP Crash Zacks
08:00AM  Today's Research Reports on Stocks to Watch: Sarepta Therapeutics and Caladrius Biosciences ACCESSWIRE
07:45AM  Sarepta's Stock Soars on Encouraging Gene Therapy Results Zacks
07:45AM  Recent Analysis Shows First Interstate BancSystem, Spectrum Brands, Sarepta Therapeutics, Capstone Turbine, Main Street Capital, and Insteel Industries Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
Jun-19-18 11:40PM  [$$] Sarepta Gets Boost From Early Trial Results on Muscular Dystrophy Treatment The Wall Street Journal +36.76%
07:57PM  More tests are needed to develop a gene therapy for a rare genetic disease: Sarepta CEO CNBC
06:10PM  Why PTC Therapeutics Dropped 30.6% Today After Jumping 27.5% Yesterday Motley Fool
05:41PM  Why Sarepta Stock Skyrocketed 40% Today Fortune
04:56PM  What Happened in the Stock Market Today Motley Fool
04:54PM  Sarepta Therapeutics Helps Biotech ETFs Buck Market Trend ETF Trends
04:38PM  [$$] Sarepta Shares Up 37% on Gene Therapy Results
04:28PM  Sarepta Gets 'Rousing Applause' And Rockets On Gene Therapy Investor's Business Daily
04:25PM  Why Sarepta Therapeutics Stock Is Blasting Higher Today Motley Fool
04:18PM  Biotech Firm Sarepta Surges 40% on Positive Test Results
02:18PM  Analyst: Sarepta's DMD Gene Therapy Results 'Dramatic And Far Exceeding Expectations' Benzinga
01:40PM  A Weak Close Is Going to Have a Significant Impact on Sentiment
01:29PM  Sarepta Shares Skyrocket on Early Results for DMD Gene Therapy
11:13AM  Cambridge biotech Sarepta tops $9B market cap on gene therapy data American City Business Journals
10:55AM  Sarepta shares rocket 55% on positive early results for DMD gene therapy MarketWatch
10:43AM  Sarepta stock soars as early-stage gene therapy data shows promise Reuters
10:41AM  Sarepta Therapeutics shares soar 50% on positive preliminary results for muscular dystrophy gene therapy CNBC
10:28AM  Sarepta Therapeutics Announces that at its First R&D Day, Jerry Mendell, M.D. Presented Positive Preliminary Results from the First Three Children Dosed in the Phase 1/2a Gene Therapy Micro-dystrophin Trial to Treat Patients with Duchenne Muscular Dystrophy GlobeNewswire
10:18AM  A Gene Therapy Appears To Replace Missing Protein In Muscular Dystrophy Patients Forbes
06:18AM  Edited Transcript of SRPT earnings conference call or presentation 19-Jul-17 8:30pm GMT Thomson Reuters StreetEvents
Sarepta Therapeutics, Inc. focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare neuromuscular diseases. The company offers EXONDYS 51, a disease-modifying therapy for the treatment of duchenne muscular dystrophy (DMD), which is a rare genetic muscle-wasting disease caused by the absence of dystrophin. It also provides Golodirsen, a product candidate that binds to exon 53 of dystrophin pre-mRNA, which results in exclusion or skipping of exon during mRNA processing in patients with genetic mutations that are amenable to exon 53 skipping; and Casimersen, a product candidate that uses phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to skip exon 45 of the DMD gene. In addition, the company provides SRP-5051, a peptide conjugated PMO that binds to exon 51 of dystrophin pre-mRNA resulting in exclusion of exon during mRNA processing in patients with genetic mutations that are amenable to exon 51 skipping. The company has strategic alliances with Nationwide Children's Hospital for the advancement of micro-dystrophin gene therapy program under the research and license option agreement, as well as Galgt2 gene therapy program under the license agreement; and Genethon for the advancement of micro-dystrophin gene therapy program under a research and exclusive license option agreement. It also has a research and license option agreement with Duke University for the advancement of gene editing CRISPR/Cas9 technology for muscular dystrophy; and a collaboration and license agreement with Summit (Oxford) Ltd. to commercialize products in Summit's utrophin modulator pipeline. The company distributes its products through a network of specialty distributors and specialty pharmacies in the United States, as well as through distributors internationally. Sarepta Therapeutics, Inc. was founded in 1980 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
INGRAM DOUGLAS SPresident & CEOAug 15Buy125.2616,0002,004,211399,250Aug 16 07:30 AM
Howton David TSVP, General CounselJul 16Option Exercise13.8550,000692,69172,719Jul 17 06:01 PM
Howton David TSVP, General CounselJul 16Sale136.4650,0006,823,00034,871Jul 17 06:01 PM
Cumbo AlexanderSVP, Chief Commercial OfficerJul 09Option Exercise13.7833,782465,41540,690Jul 11 06:05 PM
Cumbo AlexanderSVP, Chief Commercial OfficerJul 09Sale137.3233,7824,638,94428,766Jul 11 06:05 PM
Barry RichardDirectorJun 27Sale130.3475,0009,775,5003,170,432Jun 29 06:01 PM
Ruff ShamimSVP, Chief Regulatory AffairsMar 15Option Exercise23.932,50059,81329,465Mar 16 06:13 PM
Howton David TSVP, General CounselMar 15Option Exercise22.152,50055,38231,727Mar 16 06:12 PM
Cumbo AlexanderSVP, Chief Commercial OfficerMar 15Option Exercise20.642,50051,60025,767Mar 16 06:10 PM
Mahatme SandeshEVP, CFO & CBOMar 15Option Exercise23.852,50059,62543,395Mar 16 06:08 PM
Wigzell Hans Lennart RudolfDirectorNov 30Option Exercise7.386,66749,20213,333Dec 04 08:00 PM
Wigzell Hans Lennart RudolfDirectorNov 30Sale55.896,667372,6196,666Dec 04 08:00 PM
INGRAM DOUGLAS SPresident & CEONov 08Buy52.4438,1381,999,957420,196Nov 13 05:00 PM
Ruff ShamimSVP, Regulatory Affairs & QualNov 06Option Exercise14.7610,000147,60037,045Nov 08 08:13 PM
Ruff ShamimSVP, Regulatory Affairs & QualNov 06Sale55.0010,000550,00027,045Nov 08 08:13 PM
Ruff ShamimSVP, Regulatory Affairs & QualOct 03Option Exercise14.7611,500169,74038,545Oct 05 07:24 PM
Ruff ShamimSVP, Regulatory Affairs & QualOct 03Sale50.0011,500575,00027,045Oct 05 07:24 PM